https://doi.org/10.4081/reumatismo.2013.134

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

Vol. 65 No. 3 (2013)
Submitted: 4 March 2013
Accepted: 17 June 2013
Published: 24 July 2013
Certolizumab pegol, Axial spondyloarthritis, Magnetic resonance.
Abstract Views: 2518
PDF: 692
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

A. Spadaro
a.spadaro.reuma@virgilio.it
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
A. Scarno
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
A. Carboni
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
F.M. Perrotta
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
C. Catalano
Dipartimento di Medicina Molecolare, Radiologia Centrale U.O.C. A, Università “La Sapienza”, Roma, Italy.
E. Lubrano
Dipartimento di Medicina e di Scienze per la Salute, Università del Molise, Campobasso, Italy.
G. Valesini
Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma, Italy.
In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
A. Spadaro, Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma

How to Cite

Spadaro, A., Scarno, A., Carboni, A., Perrotta, F., Catalano, C., Lubrano, E., & Valesini, G. (2013). Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis. Reumatismo, 65(3), 134–137. https://doi.org/10.4081/reumatismo.2013.134

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.